Ann: Prospectus, page-3

First 3 Last

Share
Profile

Follow
sevencents77

2,956 Posts.

2

21/05/15

12:20

Post #: 15323425
Share

Originally posted by fromwell ↑

It's late and I'm tired but thought I'd quickly post some extracts and some musings ...

Investors should note that Livelynk Group’s business has only been operating in its current form of sourcing third party advertising clients from outside the Zhenya Group since July 2014. In its current form, Livelynk Group’s business should therefore be considered as having a limited operating history. Whilst revenue is currently being produced and has grown since July 2014, the business is currently loss making. Livelynk Group’s business should accordingly should be considered high risk and speculative.

For the period June 14 - Dec 14
Sales revenue 3,124,140
Cost of sales (2,635,115)
489,025

Loss from ordinary activities after tax (2,218,138)

From their revenue/cost graph, they have had revenue >900K for the last 5m straight and gross profit margin has roughly avg'd about 20% +/- 5%.
Other expenses totaled ~2.9M but ~500k appears to have been a software sale reversal which shouldn't be recurring, 100K was finance costs which may or may not recur and I haven't counted exchange differences so likely ~2.4M which is ~400K/m
So I would guess their breakeven is going to be about 2M rev/m.

Anyway, rough workings with round numbers. Take with a grain of salt or other condiment of your choice.

Expand

If I'm picking up what your putting down, it cost them 2 mil per month to run the business?

That seems exhorbanant to me.

77

FOT Price at posting: 34.0¢ Sentiment: None Disclosure: Not Held
Upvote

0 Great analysis

Reply

Top Stories

CTT

Cettire shares jump on FY24 revenue growth up 80% vs pcp – but stock still badly bruised

AX8

Accelerate finds 1.28% lithium at Prinsep in WA, including 150m 'halo' zone

NWC

New World Resources inks complete PFS for Antler Copper Project in Arizona, USA

VMM

Virdis Mining flags breakthrough with 76% neodymium and praseodymium recoveries

ATH

Trial for Alterity's neurodegenerative drug ATH434 shows reduced disability